International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) - Top-Institutions - MDSpire

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

  • By

  • María-Victoria Mateos

  • Shaji Kumar

  • Meletios A. Dimopoulos

  • Verónica González-Calle

  • Efstathios Kastritis

  • Roman Hajek

  • Carlos Fernández De Larrea

  • Gareth J. Morgan

  • Giampaolo Merlini

  • Hartmut Goldschmidt

  • Catarina Geraldes

  • Alessandro Gozzetti

  • Charalampia Kyriakou

  • Laurent Garderet

  • Markus Hansson

  • Elena Zamagni

  • Dorotea Fantl

  • Xavier Leleu

  • Byung-Su Kim

  • Graça Esteves

  • Heinz Ludwig

  • Saad Usmani

  • Chang-Ki Min

  • Ming Qi

  • Jon Ukropec

  • Brendan M. Weiss

  • S. Vincent Rajkumar

  • Brian G. M. Durie

  • Jesús San-Miguel

  • October 16, 2020

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma Research

  • #2

    Hospital Clínic de Barcelona / Spanish Myeloma Group
    Hospital Clínic de Barcelona / Spanish Myeloma Group

    Barcelona, Catalonia

    Key Differentiators

    • Hematology
    • Oncology
    • Myeloma Research

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Cancer Research

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Myeloma Research

  • #5

    University of Arkansas for Medical Sciences
    University of Arkansas for Medical Sciences

    Little Rock, AR

    Key Differentiators

    • Hematology
    • Oncology
    • Myeloma Research

Original Source(s)

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

  • by María-Victoria Mateos, Shaji Kumar, Meletios A. Dimopoulos, Verónica González-Calle, Efstathios Kastritis, Roman Hajek, Carlos Fernández De Larrea, Gareth J. Morgan, Giampaolo Merlini, Hartmut Goldschmidt, Catarina Geraldes, Alessandro Gozzetti, Charalampia Kyriakou, Laurent Garderet, Markus Hansson, Elena Zamagni, Dorotea Fantl, Xavier Leleu, Byung-Su Kim, Graça Esteves, Heinz Ludwig, Saad Usmani, Chang-Ki Min, Ming Qi, Jon Ukropec, Brendan M. Weiss, S. Vincent Rajkumar, Brian G. M. Durie, Jesús San-Miguel

  • October 16, 2020

Related Content

CRISPR Enables In Vivo CAR T Cell Production

In vivo gene editing strategy generates CAR T cells directly inside the body – sidestepping costly manufacturing

  • March 30, 2026

  • 2 min
Targeting CD38 Enzymatic Function in Antibody-Driven Immunotherapy for Multiple Myeloma: Insights from Basic Research

Case Report: Cytoreductive surgery as a therapeutic attempt in the treatment of extramedullary plasmacytoma